TTF-1蛋白和CgA蛋白在小细胞肺癌中的表达及其临床意义

doi:10.3760/cma.j.issn.1673-422X.2015.07.006

摘要/Abstract

摘要： 目的探讨甲状腺转录因子1（TTF1）蛋白和嗜铬蛋白粒A（CgA）蛋白在小细胞肺癌（SCLC）中的表达及其临床意义。方法采用免疫组织化学法检测68例SCLC组织和20例正常肺组织中TTF1蛋白和CgA蛋白的表达情况，分析其与SCLC临床特征的关系。结果TTF1蛋白和CgA蛋白在SCLC中的表达率分别为88.2%（60/68）和70.6%（48/68），均明显高于正常肺组织的10.0%（2/20）和5.0%（1/20）(χ2=45.442，P=0.000；χ2=26.941，P=0.000)。TTF1蛋白的表达与患者年龄、性别、肿瘤大小无关，而与吸烟指数(χ2=4.131，P=0.042）、淋巴结转移(χ2=5.488，P=0.019)、临床分期(χ2=6.011，P=0.014）密切相关；CgA蛋白的表达与患者年龄、性别、肿瘤大小、吸烟指数无关，而与淋巴结转移(χ2=9.895，P=0.002）、临床分期(χ2=4.145，P=0.042）密切相关。结论TTF1和CgA蛋白在SCLC高表达，尤其是有淋巴结转移和广泛期患者。

关键词: 癌, 小细胞, 嗜铬粒蛋白质A, 免疫组织化学, 甲状腺转录因子-1

Abstract: ObjectiveTo investigate the expression and clinical significance of thyroid transcription factor1 (TTF1) and chromogranin A (CgA) in small cell lung cancer (SCLC). MethodsThe expressions of TTF1 and CgA protein in 68 cases of SCLC tissues and 20 cases of normal lung tissues were examined by immunohistochemistry method, and their correlations with clinical features of SCLC were analyzed. ResultsThe positive rates of TTF1 and CgA protein in SCLC were 88.2% (60/68) and 70.6% (48/68), respectively, and they were higher than those in normal lung tissue ［10.0%(2/20) and 5.0%(1/20); χ2=45.442, P=0.000; χ2=26.941, P=0.000］. The expression of TTF1 protein was not related to the patients′ age, sex and tumor size, while closely related to smoking index (χ2=4.131, P=0.042), lymph node metastasis (χ2=5.488, P=0.019) and clinical stage (χ2=6.011, P=0.014). The expression of CgA protein was not related to the patients′ age, sex, tumor size and smoking index, while closely related to lymph node metastasis (χ2=9.895, P=0.002) and clinical stage (χ2=4.145, P=0.042). ConclusionTTF1 and CgA protein are highly expressed in SCLC, especially in the patients with lymph node metastasis and extensive disease.

Key words: Carcinoma, small cell, Chromogranin A, Immunohistochemistry, Thyroid transcription factor-1

胡思钦,张明辉,石琼,王艳. TTF-1蛋白和CgA蛋白在小细胞肺癌中的表达及其临床意义[J]. 国际肿瘤学杂志, 2015, 42(7): 501-503.

Hu Siqin, Zhang Minghui, Shi Qiong, Wang Yan. Expression and significance of TTF1 and CgA in small cell lung carcinoma[J]. Journal of International Oncology, 2015, 42(7): 501-503.

参考文献

［1］ Siegel R, Ma J, Zou Z, et al. Cancer Statistics, 2014［J］. CA Cancer J Clin, 2014, 64(1): 9-29. ［2］ Lally BE, Urbanic JJ, Blackstock AW, et al. Small cell lung cancer: have we made any progress over the last 25 years？［J］. Oncologist, 2007, 12(9): 1096-1104. ［3］ Bobos M, Hytiroglou P, Kostopoulos I, et al. Immunohistochemical distinction between merkel cell carcinoma and small cell carcinoma of the lung［J］. Am J Dermatopathol, 2006, 28(2): 99-104. ［4］ Kargi A, Gurel D, Tuna B. The diagnostic value of TTF1, CK 5/6, and p63 immunostaining in classification of lung carcinomas［J］. Appl Immunohistochem Mol Morphol, 2007, 15(4): 415-420. ［5］ Drivsholm L, Paloheimo LI, Osterlind K. Chromogranin A, a significant prognostic factor in small cell lung cancer［J］. Br J Cancer, 1999, 81(4): 667-671. ［6］ Molina R, Alvarez E, AnielQuiroga A, et al. Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies［J］. Tumor Biol, 2011, 32(1): 13-22. ［7］ Petrovi′c M, Bukumiri′c Z, Zdravkovi′c V, et al. The prognostic significance of the circulating neuroendocrine markers chromogranin A, progastrinreleasing peptide, and neuronspecific enolase in patients with smallcell lung cancer［J］. Med Oncol, 2014, 31(2): 823. ［8］周东梅, 孙宇, 李向红. 微管相关蛋白2在240例活检肺小细胞癌中的诊断价值［J］. 中华病理学杂志, 2013, 42(5): 321-324. ［9］ Sayeg Y, Sayeg M, Baum RP, et al. Pulmonary neuroendocrine neoplasms［J］. Pneumologie, 2014, 68(7): 456-477. ［10］ Hamanaka W, Motoi N, Ishikawa S, et al. A subset of small cell lung cancer with low neuroendocrine expression and good prognosis: a comparison study of surgical and inoperable cases with biopsy［J］. Hum Pathol, 2014, 45(5): 1045-1056. ［11］ DettmerM, KimTE, JungCK, et al. Thyroid transcription factor1 expression in colorectal adenocarcinomas［J］. Pathol Res Pract, 2011, 207(11): 686-690. ［12］ Robens J, Goldstein L, Gown AM, et al. Thyroid transcription factor1 expression in breast carcinomas［J］. Am J Surg Pathol, 2010, 34(12): 1881-1885. ［13］林冬梅, 邹霜梅, 吕宁, 等. 甲状腺转录因子1在肺癌中的表达及应用［J］.中华肿瘤杂志, 2004, 26(10): 615-617. ［14］ Hookim K, Kavuri S, Lauer SR, et al. Napsin A expression in small cell carcinoma of the lung: a cytologic study with review of differentials［J］. JASC, 2014, 3(1): 90-95. ［15］ Altaner S, Yoruk Y, Tokatli F, et al. The correlation between TTF1 immunoreactivity and the occurrence of lymph node metastases in patients with lung cancer［J］. Tumori, 2006, 92(4): 323-326. ［16］ Anagnostou VK, Syrigos KN, Bepler G, et al. Thyroid transcription factor 1 is an independent prognostic factor for patients with stage Ⅰ lung adenocarcinoma［J］. J Clin Oncol, 2009, 27(2): 271-278.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[3]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[4]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[5]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[6]	顾芳萌, 徐晨阳, 雷大鹏. 人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[7]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[8]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[9]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[10]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[11]	胡婷婷, 王越华. 电子鼻与线虫鼻——新型早期癌症筛查工具[J]. 国际肿瘤学杂志, 2024, 51(4): 223-226.
[12]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[13]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[14]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[15]	钱晓涛, 石子宜, 胡格. Ⅲ~ⅣA期食管鳞状细胞癌根治性放化疗后行免疫检查点抑制剂维持治疗的真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(3): 151-156.